A Form 4 filed with the SEC on September 22, 2026, discloses that Roberto Mignone, a director at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), reported the sale of 367,600 ordinary shares on September 18, 2026, held indirectly through Swiftcurrent Master Fund Ltd.

Key Highlights

  • Transaction: 367,600 ordinary shares were sold on September 18, 2026, at a weighted average price of $39.0555 per share.
  • Price range: The shares were sold in multiple transactions at prices ranging from $38.68 to $39.38, inclusive.
  • Indirect ownership: The shares were held of record by Swiftcurrent Master Fund Ltd., for which Bridger Management, LLC serves as investment adviser and Mignone serves as manager.
  • Post-transaction indirect ownership: Following the sale, indirect beneficial ownership of ordinary shares through the Fund fell to 0.
  • Direct ownership: Mignone directly holds 119,807 ordinary shares following the reported transaction.
  • Disclaimer: Mignone disclaimed beneficial ownership of the shares held by the Fund except to the extent of his indirect pecuniary interest therein.

Mignone's Indirect Share Sale via Swiftcurrent Master Fund

According to the filing, Roberto Mignone, listed as a director of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), reported a transaction dated September 18, 2026, involving the disposition of 367,600 ordinary shares. The shares were sold with a transaction code of "S," indicating an open-market sale. The weighted average sale price was $39.0555 per share, with individual transactions occurring at prices ranging from $38.68 to $39.38, inclusive. The filing notes that full information on the number of shares sold at each separate price is available upon request.

The filing explains that the 367,600 ordinary shares were held of record by Swiftcurrent Master Fund Ltd. Bridger Management, LLC is identified as the investment adviser to the Fund, and Mignone is identified as the manager of Bridger Management, LLC. The filing states that "by reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone was deemed to beneficially own the Ordinary Shares held of record by the Fund." Following this sale, Mignone's indirect beneficial ownership of ordinary shares through the Fund stands at 0, according to the filing.

Separately, the filing reports that Mignone directly holds 119,807 ordinary shares following the reported transaction. The Form 4 was signed by Dov Bergwerk as attorney-in-fact for Roberto Mignone and was filed on September 22, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing discloses the sale of 367,600 ordinary shares of Teva Pharmaceutical Industries Ltd. held indirectly by director Roberto Mignone through Swiftcurrent Master Fund Ltd., at a weighted average price of $39.0555 on September 18, 2026, with 119,807 shares remaining in direct ownership.